Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4473810
Max Phase: Preclinical
Molecular Formula: C21H18N2O7
Molecular Weight: 410.38
Molecule Type: Unknown
Associated Items:
ID: ALA4473810
Max Phase: Preclinical
Molecular Formula: C21H18N2O7
Molecular Weight: 410.38
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1ccc(C2COc3cccc4c(O)c(C(=O)NCC(=O)O)c(=O)n2c34)cc1
Standard InChI: InChI=1S/C21H18N2O7/c1-29-12-7-5-11(6-8-12)14-10-30-15-4-2-3-13-18(15)23(14)21(28)17(19(13)26)20(27)22-9-16(24)25/h2-8,14,26H,9-10H2,1H3,(H,22,27)(H,24,25)
Standard InChI Key: NUYCTCHTHNMBHY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 410.38 | Molecular Weight (Monoisotopic): 410.1114 | AlogP: 1.51 | #Rotatable Bonds: 5 |
Polar Surface Area: 127.09 | Molecular Species: ACID | HBA: 7 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.12 | CX Basic pKa: | CX LogP: 0.49 | CX LogD: -5.14 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.58 | Np Likeness Score: -0.12 |
1. Liu P, Wang L, DuBois BG, Colandrea VJ, Liu R, Cai J, Du X, Quan W, Morris W, Bai J, Bishwokarma B, Cheng M, Piesvaux J, Ray K, Alpert C, Chiu CS, Zielstorff M, Metzger JM, Yang L, Leung D, Alleyne C, Vincent SH, Pucci V, Li X, Crespo A, Stickens D, Hale JJ, Ujjainwalla F, Sinz CJ.. (2018) Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia., 9 (12): [PMID:30613325] [10.1021/acsmedchemlett.8b00274] |
Source(1):